2023
Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Analysis of Mental Health and Associated Disorders
Blauvelt A, Armstrong A, Merola J, Strober B, De Cuyper D, Peterson L, Davies O, Stark J, Lebwohl M. Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Analysis of Mental Health and Associated Disorders. SKIN The Journal Of Cutaneous Medicine 2023, 7: s300. DOI: 10.25251/skin.7.supp.300.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsPHQ-9 scoresPHQ-9Severe plaque psoriasisLonger-term depressionPlaque psoriasisModerate-severe depressionRisk of depressionSuicidal ideationPatient Health Questionnaire (PHQ)-9Moderate to severe plaque psoriasisPHQ-9 dataElevated PHQ-9 scoresGeneral psoriasis populationAnalysis of mental healthDepressionMental healthHigher scoresSuicideLong-term incidence rateAdverse eventsPsoriasis populationScore 0Adjudication committeeWk16
2012
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
Papp K, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. Journal Of Drugs In Dermatology 2012, 11: 1210-7. PMID: 23134986.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArthritis, PsoriaticBody Mass IndexBody Surface AreaCardiovascular DiseasesData Interpretation, StatisticalFemaleHumansImmunologic FactorsInfliximabMaleMiddle AgedObesityPhototherapyProduct Surveillance, PostmarketingProspective StudiesPsoriasisRegistriesUstekinumabConceptsDisease-based registryBiologic agentsObservational studyMajor adverse cardiovascular eventsConventional systemic treatmentsGeneral psoriasis populationPsoriasis Longitudinal AssessmentAdverse cardiovascular eventsOverweight/obeseLong-term observational studyBody surface areaPsoriasis populationCardiovascular eventsCause mortalityAdverse eventsPsoriatic arthritisRegistry studySystemic agentsSystemic therapySystemic treatmentMedication historyDisease characteristicsSerious infectionsMean durationEfficacy dataBiopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know
Strober B, Armour K, Romiti R, Smith C, Tebbey P, Menter A, Leonardi C. Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know. Journal Of The American Academy Of Dermatology 2012, 66: 317-322. PMID: 22243723, DOI: 10.1016/j.jaad.2011.08.034.Peer-Reviewed Original ResearchConceptsTreatment of psoriasisOptimal therapy managementImmune-mediated disordersBiosimilar formPsoriasis populationAppropriate therapyTopical agentsTherapy managementBiosimilar agentsClinical relevanceGeneric therapiesPatient careTherapyPsoriasisImportant interventionDevelopment of biosimilarsPatientsBiosimilarsDermatologistsTreatmentBiopharmaceutical therapiesAgentsImportant differencesPrescribersRegulatory guidelines